|
1
|
Wang YW, Yin CL, Zhang HY, Hao J, Yang YY,
Liao H and Jiao BH: High expression of forkhead box protein C2 is
related to poor prognosis in human gliomas. Asian Pac J Cancer
Prev. 15:10621–10625. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Islam KM Monirul, Shostrom V, Kessinger A
and Ganti AK: Outcomes following surgical treatment compared to
radiation for stage I NSCLC: A SEER database analysis. Lung Cancer.
82:90–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gridelli C, Peters S, Sgambato A, Casaluce
F, Adjei AA and Ciardiello F: ALK inhibitors in the treatment of
advanced NSCLC. Cancer Treat Rev. 40:300–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roemans P, Emami B, Cox J, Pacagnella A,
Holsti L, Monteau M, Helle P, Comis R and Schaake C: Quality
control in NSCLC treatment: A consensus report. Lung Cancer.
7:19–20. 1991. View Article : Google Scholar
|
|
5
|
Pircher A, Manzl C, Fiegl M, Popper H,
Pirker R and Hilbe W: Overcoming resistance to first generation
EGFR TKIs with cetuximab in combination with chemotherapy in an
EGFR mutated advanced stage NSCLC patient. Lung Cancer. 83:408–410.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han SY, Zhao MB, Zhuang GB and Li PP:
Marsdenia tenacissima extract restored gefitinib sensitivity in
resistant non-small cell lung cancer cells. Lung Cancer. 75:30–37.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koizumi T, Agatsuma T, Ikegami K, Suzuki
T, Kobayashi T, Kanda S, Yoshikawa S, Kubo K, Shiina T, Takasuna K,
et al: Prospective study of gefitinib readministration after
chemotherapy in patients with advanced non-small-cell lung cancer
who previously responded to gefitinib. Clin Lung Cancer.
13:458–463. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grigoriu B, Berghmans T and Meert AP:
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Eur Respir J. 45:1132–1141. 2001. View Article : Google Scholar
|
|
9
|
Dhillon S: Gefitinib: A review of its use
in adults with advanced non-small cell lung cancer. Target Oncol.
10:153–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manegold C: New perspectives in the
management of non-small cell lung cancer (NSCLC): Gefitinib
(Iressa, ZD 1839). European Journal of Cancer Supplements. 2:34–39.
2004. View Article : Google Scholar
|
|
11
|
Jeong CH, Park HB, Jang WJ, Jung SH and
Seo YH: Discovery of hybrid Hsp90 inhibitors and their
anti-neoplastic effects against gefitinib-resistant non-small cell
lung cancer (NSCLC). Bioorg Med Chem Lett. 24:224–227. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
MacDonagh L, Gray SG, Finn SP, Cuffe S,
O'Byrne KJ and Barr MP: The emerging role of microRNAs in
resistance to lung cancer treatments. Cancer Treat Rev. 41:160–169.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tandon R, Kapoor S, Vali S, Senthil V,
Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar
PK and Dastidar SG: Dual epidermal growth factor receptor
(EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A
novel approach for overcoming resistance in anticancer treatment.
Eur J Pharmacol. 667:56–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Tang N, Hui T, Wang S, Zeng X, Li
H and Ma J: Identification of endogenous reference genes for
RT-qPCR analysis of plasma microRNAs levels in rats with
acetaminophen-induced hepatotoxicity. J Appl Toxicol. 33:1330–1336.
2013.PubMed/NCBI
|
|
18
|
Grossi F and Tiseo M: Granulocyte growth
factors in the treatment of non-small cell lung cancer (NSCLC).
Crit Rev Oncol Hematol. 58:221–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mukohara T, Kudoh S, Yamauchi S, Kimura T,
Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue
K and Yoshikawa J: Expression of epidermal growth factor receptor
(EGFR) and downstream-activated peptides in surgically excised
non-small-cell lung cancer (NSCLC). Lung Cancer. 41:123–130. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pallis AG and Syrigos KN: Epidermal growth
factor receptor tyrosine kinase inhibitors in the treatment of
NSCLC. Lung Cancer. 80:120–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han X, Liu M, Wang S, Lv G, Ma L, Zeng C
and Shi Y: An integrative analysis of the putative
gefitinib-resistance related genes in a lung cancer cell line model
system. Curr Cancer Drug Targets. 15:423–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Van Emburgh BO, Sartore-Bianchi A, Di
Nicolantonio F, Siena S and Bardelli A: Acquired resistance to
EGFR-targeted therapies in colorectal cancer. Mol Oncol.
8:1084–1094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang KE, Kwon SJ, Kim YS, Park DS, Kim
BR, Yoon KH, Jeong ET and Kim HR: Effect of simvastatin on the
resistance to EGFR tyrosine kinase inhibitors in a non-small cell
lung cancer with the T790M mutation of EGFR. Exp Cell Res.
323:288–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao Z, Liu LZ, Dixon DA, Zheng JZ,
Chandran B and Jiang BH: Insulin-like growth factor-I induces
cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling
pathways in human ovarian cancer cells. Cell Signall. 19:1542–1553.
2007. View Article : Google Scholar
|
|
25
|
Kim MN, Lee KE, Hong JY, Heo WI, Kim KW,
Kim KE and Sohn MH: Involvement of the MAPK and PI3K pathways in
chitinase 3-like 1-regulated hyperoxia-induced airway epithelial
cell death. Biochem Biophys Res Commun. 421:790–796. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang CY, Kuan YH, Ou YC, Li JR, Wu CC,
Pan PH, Chen WY, Huang HY and Chen CJ: Autophagy contributes to
gefitinib-induced glioma cell growth inhibition. Exp Cell Res.
327:102–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu R, Shen H, Guo R, Sun J, Gao W and Shu
Y: Combine therapy of gefitinib and fulvestrant enhances antitumor
effects on NSCLC cell lines with acquired resistance to gefitinib.
Biomed Pharmacother. 66:384–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong M, Ma X, Sun C and Chen L: MicroRNAs
reduce tumor growth and contribute to enhance cytotoxicity induced
by gefitinib in non-small cell lung cancer. Chem Biol Interact.
184:431–438. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou JY, Chen X, Zhao J, Bao Z, Chen X,
Zhang P, Liu ZF and Zhou J: MicroRNA-34a overcomes HGF-mediated
gefitinib resistance in EGFR mutant lung cancer cells partly by
targeting MET. Cancer Lett. 351:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng B, Wang R and Chen LB: Review of
MiR-200b and cancer chemosensitivity. Biomed Pharmacother.
66:397–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ochi N, Takigawa N, Harada D, Yasugi M,
Ichihara E, Hotta K, Tabata M, Tanimoto M and Kiura K: Src mediates
ERK reactivation in gefitinib resistance in non-small cell lung
cancer. Exp Cell Res. 322:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Q, Guo R, Lin M, Zhou B and Wang Y:
MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration
and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol.
122:149–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
